Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosaroxin + azacitidine in older patients with newly diagnosed AML or MDS-EB-2
2015-004066-28Phase 2Terminated
- Sponsor
- University Hospital Ulm
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vosaroxin and azacitidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University Hospital Ulm. Primary endpoint: Rate of complete remission and complete remission with incomplete blood count recovery. Started Nov 2017; status: terminated.
02
Drugs
vosaroxinazacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2015-004066-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004066-28.